Sanofi

This early-stage study tests a new vaccine called VXB-241 in healthy adults aged 60-83, with a smaller group of younger adults (18-40) first. The vaccine is designed to protect against two viruses that can cause serious lung infections: RSV and HMPV. Researchers will check how sa…

This early-stage study tests a new vaccine called VXB-251 in 240 healthy adults aged 60-83. The vaccine is designed to protect against three viruses that can cause serious lung infections: RSV, hMPV, and PIV3. Researchers will check if the vaccine is safe and how well it triggers…

This Phase 3 study is testing an investigational meningococcal conjugate vaccine (MenACYW) in over 1,600 healthy children and adolescents aged 2 to 17 in China. The vaccine aims to protect against four types of meningococcal bacteria that can cause serious infections like meningi…

This phase 3 study tests whether a new 21-valent pneumococcal vaccine (PCV21) is safe for healthy infants. About 2360 babies will receive either PCV21 or the current Prevnar 20 vaccine at 2, 4, 6, and 12-15 months old. Researchers will monitor for side effects like injection-site…

This study tests a new 21-valent pneumococcal conjugate vaccine (PCV21) in about 1,092 healthy infants and toddlers. The goal is to see if PCV21 is safe and helps the body produce antibodies against pneumococcal bacteria better than the current licensed vaccine. Participants rece…

This Phase 3 study tests whether mixing a new 21-valent pneumococcal vaccine with a licensed 20-valent version is safe and helps build immunity in healthy infants. About 580 babies will receive different combinations of the vaccines at routine checkups. The goal is to see if flex…

This study tests a new mRNA vaccine designed to protect against a potential pandemic flu caused by the H5 virus. Healthy adults aged 18 and older will receive either a high, medium, or low dose of the vaccine or a placebo. The goal is to see if the vaccine is safe and triggers a …

This study tests a new injectable drug called lunsekimig in adults with high-risk asthma who cannot currently use other biologic treatments. The goal is to see if it can reduce asthma attacks and improve breathing over about a year. Around 1,147 participants will receive either t…

This phase 2b trial tests frexalimab, an antibody that calms the immune system, in 192 adults and teens newly diagnosed with type 1 diabetes. The goal is to see if it can preserve the body's ability to produce insulin, reducing reliance on injections. Participants receive frexali…

This study follows 16 infants aged 6 months or younger with infantile-onset Pompe disease, a rare genetic disorder that weakens muscles and breathing. All receive alglucosidase alfa (Myozyme) as part of their routine care. Researchers track how many survive without needing a brea…

This phase 3 study tests whether venglustat, an experimental oral drug, can slow heart thickening better than current standard treatments in 104 adults with Fabry disease. Participants are randomly assigned to venglustat or usual care (enzyme replacement or migalastat) for 18 mon…

This study tests whether dupilumab can help people with moderate to severe ulcerative colitis that has a certain type of immune cell activity (eosinophilic phenotype). About 68 adults will receive either dupilumab or a placebo for 52 weeks. The main goal is to see if symptoms and…

This Phase 3 study tests the long-term safety of itepekimab, an injected drug, in 380 adults with chronic sinusitis and nasal polyps that are hard to control. Participants previously completed a one-year study on itepekimab. The trial lasts up to 72 weeks and also checks if the d…

This study looks at the long-term safety and effectiveness of a drug called lunsekimig for adults with asthma. Participants have already completed a previous study with the same drug. They will receive lunsekimig injections for up to 144 weeks. The goal is to see if the drug rema…

This study is a long-term extension of earlier trials testing the drug riliprubart in adults with CIDP, a condition where the immune system attacks the nerves, causing weakness and numbness. About 300 participants who completed a prior riliprubart study will continue receiving th…

This study tests an experimental drug called rilzabrutinib in 22 adults with warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells. Participants take the drug daily for up to 24 weeks, with an option to continue longer. The main goa…

This Phase 3 trial tests itepekimab, an injectable drug, in 216 adults with chronic sinusitis and nasal polyps that are not well-controlled by standard nasal sprays. Participants receive itepekimab or a placebo for 52 weeks, plus a nasal spray. The study measures changes in polyp…

This long-term study is testing the safety and effectiveness of amlitelimab, an injected drug, in over 1600 people with moderate to severe atopic dermatitis (eczema) who have already taken part in earlier amlitelimab trials. Some participants will stop treatment temporarily to se…

This study looks at the long-term safety and effectiveness of balinatunfib, an oral tablet, in adults with Crohn's disease or ulcerative colitis. Participants have already completed a one-year treatment in a previous study. The trial will last up to 107 weeks and includes both do…

This study looks at the long-term safety and effectiveness of lunsekimig, an injectable drug, in adults with chronic sinusitis and nasal polyps that are not well controlled. Participants have already completed a previous lunsekimig study and will continue treatment for up to 52 w…

This study looks at the long-term safety and effectiveness of a drug called amlitelimab for adults with moderate-to-severe asthma. Participants have already completed a previous amlitelimab study. They will receive injections of amlitelimab or a placebo for up to 144 weeks. The g…

This study looks at the long-term safety of a drug called itepekimab for people with chronic obstructive pulmonary disease (COPD). About 700 adults who already completed earlier itepekimab studies will receive the drug every 2 or 4 weeks for up to 52 weeks, plus a 20-week follow-…

This phase 3 trial compares the experimental drug frexalimab to the approved drug teriflunomide in about 1,655 adults with relapsing multiple sclerosis. The main goal is to see if frexalimab reduces the number of relapses more effectively. Participants receive either frexalimab i…

This study tests an experimental drug called frexalimab in people with a type of progressive multiple sclerosis (MS) that is no longer causing relapses. The goal is to see if the drug can delay worsening disability compared to a placebo. About 943 adults aged 18 to 60 are taking …

This study offers continued treatment with isatuximab (a targeted antibody) to adults with multiple myeloma who were already benefiting from it in earlier trials. About 70 participants will receive the drug, possibly combined with other medications, to monitor long-term safety. T…

This study tests whether adding isatuximab to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) can help people with newly diagnosed multiple myeloma who cannot have a stem cell transplant live longer without their cancer worsening. About 475 participant…

This Phase 2 trial tests an oral drug called SAR443122 in 187 adults with moderate to severe ulcerative colitis who haven't responded well to other treatments. Participants receive either the drug or a placebo for up to 52 weeks. The goal is to see if the drug can safely help ach…

This study is testing the long-term safety and effectiveness of a drug called amlitelimab for people aged 12 and older with moderate to severe atopic dermatitis (eczema). Participants receive injections of amlitelimab for up to 5 years, and researchers monitor for side effects an…

This study tests whether a drug called amlitelimab can keep eczema under control for a full year in people aged 12 and older with moderate-to-severe atopic dermatitis. Participants who already responded to treatment in an earlier study will either continue the drug or receive a p…

This study tests whether dupilumab, an injectable biologic, can slow the decline of lung function in adults with uncontrolled moderate to severe asthma. Over 1,300 participants will receive either dupilumab or a placebo for three years, alongside their usual asthma medications. T…

This study tests a new drug called SAR447537 (INBRX-101) in 185 adults with alpha-1 antitrypsin deficiency (AATD) emphysema, a genetic condition that causes lung damage. The drug is a lab-made protein designed to replace the missing enzyme and slow disease progression. The main g…

This study looks at how well dupilumab (Dupixent) works over two years in about 48 children aged 6 to 14 with moderate-to-severe eczema. The main goal is to see if the drug improves the skin's barrier function, measured by water loss through the skin. All participants receive dup…

This study tests a fixed-dose combination of insulin glargine and lixisenatide (iGlarLixi) in 105 adults with type 2 diabetes whose blood sugar is not well controlled on oral drugs or other injectables. The main goal is to check safety and side effects, while also measuring chang…

This study tests a new enzyme replacement therapy called avalglucosidase alfa in babies with infantile-onset Pompe disease, a rare genetic disorder that causes severe muscle weakness and breathing problems. The treatment is given through an IV every other week for up to 4 years. …

This Phase 2 trial tests whether the experimental drug SAR441344 can safely control disease activity in people with active systemic lupus erythematosus (SLE). About 109 adults aged 18–70 will receive either the drug or a placebo for 24 weeks. The main goal is to see if more peopl…

This study tests brivekimig, a drug that targets inflammation, to see if it can help people with newly diagnosed type 1 diabetes keep making their own insulin. About 84 adults and adolescents will receive either brivekimig or a placebo for 52 weeks. The main goal is to measure in…

This phase 2 trial tests a drug called BIVV020 in 48 kidney transplant recipients. The goal is to see if it can prevent or treat antibody-mediated rejection, a common cause of transplant failure. Participants receive BIVV020 plus standard care, and researchers monitor rejection r…

This study tests a drug called amlitelimab in adults with celiac disease who still have symptoms even after following a gluten-free diet for at least a year. About 229 participants will receive either the drug or a placebo as a shot under the skin for up to 28 weeks. The goal is …

This study tests the long-term safety of the drug tolebrutinib in 2,500 adults with relapsing or progressive multiple sclerosis. Participants previously took part in earlier trials and will continue taking tolebrutinib or a placebo for up to several years. The goal is to see if t…

This phase 3 trial tests fitusiran, an injectable drug, in 91 males aged 12 and older with severe hemophilia A or B, with or without inhibitors. Participants first receive standard care for 6 months, then switch to fitusiran for about 3 years. The goal is to see if fitusiran redu…

This study tests a drug called teplizumab in 20 children under 8 who have early signs of type 1 diabetes (Stage 2). The goal is to check if the drug is safe and how the body handles it. Teplizumab works by calming the immune system to protect insulin-making cells. If successful, …

This phase 2 study follows 9 adults with Usher syndrome type 1B who previously received a single injection of the gene therapy SAR421869 under their retina. Researchers are monitoring long-term safety and whether the treatment can slow retinal degeneration. The trial is active bu…

This study tests a drug combination (isatuximab, carfilzomib, and dexamethasone) given under the skin to adults whose multiple myeloma has returned or stopped responding to prior treatments. The main goal is to see how well the cancer responds and to compare two ways of giving th…

This study tests a medication called dupilumab in 69 adults with eosinophilic esophagitis, a condition that makes swallowing difficult due to inflammation and scarring in the esophagus. Participants receive either dupilumab or a placebo for 24 weeks, then everyone gets dupilumab …

This phase 3 trial tests whether adding isatuximab (Sarclisa) to standard lenalidomide and dexamethasone can delay progression to active multiple myeloma in people with high-risk smoldering myeloma. About 337 participants will receive either the three-drug combo or the two-drug s…

This study tests if a shot under the skin works as well as an IV infusion for a multiple myeloma drug combination. About 531 adults with relapsed or hard-to-treat myeloma are taking part. The goal is to see if the shot gives similar cancer-fighting results and is easier for patie…

This study is for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding and bruising. It tests the long-term safety and benefit of an oral drug called rilzabrutinib. Only 4 participants who already benefited fr…

This phase 3 trial tests venglustat, a daily oral drug, against the standard IV treatment Cerezyme in 43 people with Gaucher disease type 3. Participants must have been on enzyme replacement therapy for at least 3 years. The goal is to see if venglustat can stabilize or improve n…

This study tests whether adding the drug belumosudil to standard steroids helps control chronic graft-versus-host disease (cGVHD) better than steroids alone. cGVHD is a serious condition where donor immune cells attack the recipient's body after a stem cell transplant. About 260 …

This Phase 2 trial tests a drug called SAR441344, which blocks a protein (CD40L) involved in immune attacks. The goal is to see if it can reduce new active brain lesions in people with relapsing multiple sclerosis. About 129 adults aged 18-55 with relapsing MS are participating, …

This study follows about 200 people with hemophilia A who are already taking a medicine called efanesoctocog alfa as part of their routine care. Researchers want to see how well it protects joints from bleeding over 5 years. No new treatments are given—just observation of real-wo…

This study tests a one-time gene therapy called SAR444836 for adults with phenylketonuria (PKU), a genetic disorder that makes it hard to break down an amino acid called phenylalanine. The therapy uses a harmless virus to deliver a working copy of the missing gene. Researchers wa…

This study follows 100 adults with prurigo nodularis who are already prescribed dupilumab (Dupixent) by their doctor. Researchers will track why patients start or stop the drug, how well it controls itching and skin bumps, and any hospital visits. The goal is to see how dupilumab…

This study looks at how safe and effective nirsevimab is at preventing severe RSV in babies and young children. About 110 infants and toddlers up to 24 months old will receive the medicine as part of their regular care. Researchers will track side effects and how many children ge…

This study tests a drug called itepekimab in adults with chronic sinusitis and nasal polyps that are not well controlled by standard treatments. About 231 participants will receive either itepekimab or a placebo as an add-on to their usual nasal spray. The goal is to see if the d…

This study tests an experimental drug called itepekimab in 66 adults with chronic sinusitis who have not improved with standard treatments. Participants receive either the drug or a placebo for 24 weeks. The goal is to see if itepekimab can reduce sinus inflammation and ease symp…

This study tests whether venglustat can reduce nerve pain in the arms and legs, and belly pain, in people with Fabry disease. Participants are 16 or older and have not had Fabry treatment for at least 6 months. The trial lasts 12 months, with visits every 3 months, and compares v…

This Phase 3 trial tests whether dupilumab (Dupixent) can reduce severe itching in adults with lichen simplex chronicus, a skin condition causing intense itch. 142 participants will receive either dupilumab or placebo injections for 24 weeks. The main goal is to see if more peopl…

This Phase 3 trial tests whether dupilumab (Dupixent) injections can reduce severe itching in adults with lichen simplex chronicus, a skin condition causing intense, persistent itch. About 138 participants will receive either dupilumab or a placebo for 24 weeks. The main goal is …

This study follows 150 adults in France with severe chronic rhinosinusitis and nasal polyps who are already taking dupilumab (Dupixent®). Researchers will collect data on patient characteristics, disease history, and treatment patterns over two years. The goal is to see how the d…

This study looks at two medicines, alirocumab and inclisiran, that help lower bad cholesterol (LDL-C) in people with heart disease. Researchers will use real-world data from about 124 patients to see which drug reduces cholesterol more over time. The goal is to understand how the…

This study follows 78 adults in Taiwan who have Fabry disease and carry a specific genetic mutation called GLA IVS4. Researchers are looking at how the disease affects the heart and other organs over time, both in people who have never been treated and those who have received aga…

This study is using electronic medical records from about 365,000 pregnant women in the U.S. to check the safety of the Adacel vaccine, which protects against tetanus, diphtheria, and whooping cough. Researchers will compare pregnancy and birth outcomes between women who got the …

This study follows 143 children aged 6 months to 11 years with severe atopic dermatitis (eczema) who are starting treatment with dupilumab in Spain. Researchers will observe how the drug is used in everyday practice, its effectiveness, and any side effects over two years. No extr…

This study follows 376 people aged 12 and older who are starting Dupixent for asthma in real-world clinics. Researchers will track their medical history, how they use the drug, and whether it improves lung function and reduces attacks. No new treatment is given—the goal is to lea…